{
    "nctId": "NCT01208441",
    "briefTitle": "RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer",
    "officialTitle": "A Phase Ib Neoadjuvant Study of the Gamma Secretase Inhibitor (RO4929097) in Combination With the Aromatase Inhibitor Letrozole in Post-Menopausal Women With Stage II/III Hormone Receptor-Positive Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 28,
    "primaryOutcomeMeasure": "MTD defined as the dose level at which no more than 1 of 6 patients experience a DLT, and the dose below that at which at least 2/6 patients have DLT according to NCI CTCAE version 4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically confirmed invasive breast cancer\n\n  * Stage II or III disease (T2-T3, N0-2)\n\n    * No N3, T4 disease\n  * Estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+)\n\n    * H score \u2265 10 or positivity \u2265 10%\n  * HER2 negative as determined by IHC (1 or 2+) or FISH (\\< 2.0+)\n* Bilateral disease allowed as long as all tumors are ER+ and \u2265 1 is T2-T3\n* Patient must have disease that is palpable on physical exam and able to be imaged via breast ultrasound\n\n  * Defined as \u2265 1 T2 tumor \\> 2 cm\n  * Multifocal disease allowed provided that \u2265 1 of the tumors is \\> 2 cm\n* No metastatic disease by CT scans of the chest, abdomen, and pelvis, a PET/CT bone scan, or nuclear medicine bone scan\n* No inflammatory breast cancer or presence of breast tumor cells in the dermal lymphatics of the breast\n* Post-menopausal meeting 1 of the following criteria:\n\n  * Bilateral oophorectomy\n  * Age \u2265 50 years and amenorrheic for \\> 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression (spontaneous amenorrhea)\n* ECOG performance status (PS) 0-2 (Karnofsky PS 60-100%)\n* Life expectancy \\> 3 months\n* ANC \u2265 1,000/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Hemoglobin \u2265 9 g/dL\n* Total bilirubin normal\n* AST and ALT \u2264 2.5 times upper limit of normal\n* Creatinine normal OR creatinine clearance \u2265 60 mL/min\n* Baseline QTcF \u2264 470 msec\n* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma secretase inhibitor RO4929097 or other agents used in the study\n* No malabsorption syndrome or other condition that would interfere with intestinal absorption\n* Able to swallow tablets\n* Not serologically positive for hepatitis A, B, or C, or have a history of liver disease, other forms of hepatitis, or cirrhosis\n* No uncontrolled electrolyte abnormalities including hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia despite adequate electrolyte supplementation\n* No uncontrolled intercurrent illness including, but not limited to, any of the following:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * History of torsades de pointes or other significant cardiac arrhythmia other than chronic, stable atrial fibrillation\n  * Psychiatric illness and/or social situations that would limit compliance with study requirements\n* Recovered to \\< grade 2 CTCAE toxicities related to prior therapy\n* No prior chemotherapy, hormonal therapy, radiotherapy, or biological therapy for breast cancer\n\n  * Prior treatment for non-melanoma skin cancer or carcinoma in situ of the cervix allowed\n  * No prior hormone therapy for ductal carcinoma in situ (DCIS)\n* No other concurrent investigational agents\n* No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin\u00ae)\n* No concurrent medications that are strong inducers and/or inhibitors or substrates of CYP3A4\n\n  * Switching to alternative medications allowed\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No concurrent antiarrhythmics or other medications known to prolong QTc\n* No other concurrent anticancer agents or therapies\n* No concurrent grapefruit juice",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}